The Bear Flag That Won't Be...Beyond the successful breakout of the stochastic AND the crossover of the MACD, MindMed had a positive earnings report that beat expectations.
All of the pieces are in play for this pattern to play out against expectations - and the break to the upside seems imminent.
You don't have to (and legally shouldn't) listen to me, but I'm sitting happily on my September '22 call options
Clinical
$LCTX biotech company analysis *This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
My team has been following clinical-stage biotech company $LCTX for the past few months. $LCTX pipeline looks very promising. We believe that current price levels are undermining the companies potential. We entered $LCTX on 5/14/21 at $2.23 per share and have been holding ever since. Following its correction from its 52-week high of $3.13 $LCTX now sits at $2.80 per share.
My team averaged up on our $LCTX position this morning at $2.70 per share and intend to take profit at $4.20.
ORIGINAL ENTRY: $2.23
AVERAGING UP AT: $2.70
TAKE PROFIT: $4.20
STOP PROFIT LOSS: $2.50
If you want to see more, please like and follow us @SimplyShowMeTheMoney
AVEO missed earnings - kidney cancer treatment too thinly tradedMedical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
Nordic Nanovector to make a new attempt at breaking downtrend?Technicals:
Nordic Nanovector retraced from recent high to fill gaps down to support at NOK 48, which triggered a strong reversal pattern.
Investors will be keen to follow if the stock establishes a trading range above 53 NOK which would represent a breakout from the recent downtrend, and even more if the stock could possibly break free from the almost two year long main downtrend from ATH in december 2016.
Fundamentals:
Reversal could be helped by this weeks news that Nordic Nanovector will be presenting three posters at this years ASH conference.
nanoinvestors.wordpress.com
At the same time Jefferies Financial group published a BUY recommendation for $NANO.OL with target price 115 NOK, representing a more than 100% upside from todays level.
nanoinvestors.wordpress.com
Nordic Nanovector was also mentioned as a possible target of M&A interest by nordic brokerage ABG Sundal Collier
nanoinvestors.wordpress.com
$AITB - AIT Therapeutics Inc - Buy AlertAIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and for nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com
$CTRV Runway Is Cleared for Take-Off$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to move a stock and takes care of his shareholders while at the same time taking care of the company and business. Not to mention 3 drug candidates in clinical trials. Liking what I'm seeing here.
BKIT bounce play with clinical trials"team appointed to conduct clinical trials of its insomnia products using Blake’s proprietary Zleepax™ formula"
This looks like a typical reversal play after a huge run up. The news from March 2 introduces the team behind the clinical study. There is a huge market for this. Could be a nice reversal play here.
www.otcmarkets.com
Outstanding Shares 31,597,572 a/o May 01, 2017